Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer

Ann Transl Med. 2023 Mar 15;11(5):229. doi: 10.21037/atm-22-6389. Epub 2023 Jan 29.

Authors

Hidekatsu Nakai¹, Noriomi Matsumura¹

Affiliation

¹ Department of Obstetrics and Gynecology, Faculty of Medicine, Kindai University, Osaka, Japan.

No abstract available

Keywords: BOOST trial; Ovarian cancer; bevacizumab.

Publication types

Editorial
Comment